Scientists test drug combo for Tough-to-Treat prostate cancer
NCT ID NCT02123758
Summary
This early-stage study is checking how two prostate cancer drugs, JNJ-56021927 and abiraterone acetate, interact in the body when taken together. It involves 57 men whose prostate cancer has spread and is no longer responding to standard hormone-blocking treatments. The main goals are to see if the combination is safe and to understand how the drugs affect each other, which could guide future treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Los Angeles, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Houston, Texas, United States
-
Study site
Vancouver, British Columbia, Canada
-
Study site
Montreal, Quebec, Canada
-
Study site
Rotterdam, Netherlands
-
Study site
Sutton, United Kingdom
Conditions
Explore the condition pages connected to this study.